Unknown

Dataset Information

0

Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.


ABSTRACT: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).Patients received aclidinium 400 ?g twice daily (morning and evening), tiotropium 18 ?g once daily (morning), or placebo for 6 weeks. The primary endpoint was change from baseline in forced expiratory volume in 1 second area under the curve for the 24-hour period post-morning dose (FEV1 AUC0-24) at week 6. Secondary and additional endpoints included FEV1 AUC12-24, COPD symptoms (EXAcerbations of chronic pulmonary disease Tool-Respiratory Symptoms [E-RS] total score and additional symptoms questionnaire), and safety.Overall, 414 patients were randomized and treated (FEV1 1.63 L [55.8% predicted]). Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (? = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (? = 140 mL and 123 mL, respectively; p < 0.0001) at week 6. Significant improvements in E-RS total scores over 6 weeks were numerically greater with aclidinium (p < 0.0001) than tiotropium (p < 0.05) versus placebo. Only aclidinium significantly reduced the severity of early-morning cough, wheeze, shortness of breath, and phlegm, and of nighttime symptoms versus placebo (p < 0.05). Adverse-event (AE) incidence (28%) was similar between treatments. Few anticholinergic AEs (<1.5%) or serious AEs (<3%) occurred in any group.Aclidinium provided significant 24-hour bronchodilation versus placebo from day 1 with comparable efficacy to tiotropium after 6 weeks. Improvements in COPD symptoms were consistently numerically greater with aclidinium versus tiotropium. Aclidinium was generally well tolerated.

SUBMITTER: Beier J 

PROVIDER: S-EPMC3787813 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5476673 | BioStudies
2019-01-01 | S-EPMC6435124 | BioStudies
2015-01-01 | S-EPMC4531806 | BioStudies
2016-01-01 | S-EPMC5174811 | BioStudies
2015-01-01 | S-EPMC4655912 | BioStudies
2016-01-01 | S-EPMC4833795 | BioStudies
2014-01-01 | S-EPMC4213545 | BioStudies
2003-01-01 | S-EPMC1746483 | BioStudies
2019-01-01 | S-EPMC6396834 | BioStudies
1000-01-01 | S-EPMC3772873 | BioStudies